Amarantus Bioscience Holdings Inc (AMBS)

[GS1]

ESS has huge potential


Amarantus estimates the target patient population in the U.S. that would qualify for the study (i.e. TBSA = 50%) is between 500 and 2000 individuals. However, management believes that approximately 100,000 patients have burns with TBSA = 30%, meaning that a large market opportunity exists to expand the ESS development path should the initial Phase 2a study prove successful. On a global basis, burns with TBSA = 30% affect over 1 million.

The cost to care for a severely burned patient can range from $200,000 to over $1 million in hospital and physician’s fees alone.

In US, total patients with TBSA >= 50% is 2000.
In US, total patients with TBSA >= 30% is 100,000.

Cost per patient 200,000 to 1 million. I will take 500K as Average Cost.

TBSA >= 50% -> 2000 X 500,000 = 1,000,000,000 (1 Billion)
TBSA >= 30% -> 100,000 X 500,000 = 50,000,000,000 (50 Billion)

This is only US Market. Global market is estimated to have 1 million patients.
So 1,000,000 X 500,000 = 500 Billion Dollars Global Maket opportunity.